An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer

@article{Bonnefoi2001AnEP,
  title={An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer},
  author={Herv{\'e} R. Bonnefoi and Laura Biganzoli and Tanja {\vC}ufer and Louis Mauriac and Audrey Hamilton and Peter Schaefer and Martine J. Piccart},
  journal={Breast Cancer Research and Treatment},
  year={2001},
  volume={70},
  pages={55-63}
}
Purpose. The association of continuous infusion 5-fluorouracil, epirubicin (50mg/m2 q 3weeks) and a platinum compound (cisplatin or carboplatin) was found to be very active in patients with either locally advanced/inflammatory (LA/I) [1, 2] or large operable (LO) breast cancer (BC) [3]. The same rate of activity in terms of response rate (RR) and response duration was observed in LA/I BC patients when cisplatin was replaced by cyclophosphamide [4]. The dose of epirubicin was either 50mg/m2 [1… CONTINUE READING